Cognition Therapeutics shares rise 1.93% intraday after Nature Aging study links FTL1 protein reduction to reversing age-related memory loss.
ByAinvest
Thursday, Aug 21, 2025 11:27 am ET1min read
CGTX--
Cognition Therapeutics, Inc. rose 1.93% intraday, following the publication of a study in Nature Aging showing that reducing FTL1 protein can reverse age-related memory loss in the brain, directly relevant to the treatment of cognitive diseases. The company, which focuses on developing drugs for neurodegenerative diseases, also announced the initiation of an expanded access program for zervimesine to treat Lewy body dementia on June 3, 2025, demonstrating progress in its core business.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet